Wednesday, June 10, 2026

pharma Β· Chronic kidney disease Β· Advanced solid tumors

Bayer

Bayer clinical programs β€” 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE HQ
97,894 Employees
EMA registrant Type
Company details
Status
Public
HQ
Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE
Employees
97,894
Programs
47
Drugs
62
Patents
5
Intelligence Β· Clinical Programs

Bayer projects

2 ClinicalTrials.gov programs sponsored by Bayer.

Bayer has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 20510

    Bayer AG

    metastatic castrate resistant prostate cancer (mCRPC)

    approved small molecule active

    1 trial
  2. Eylea 114.3 mg/ml solution for injection

    Bayer AG

    Neovascular age-related macular degeneration (nAMD), Diabetic macular edema (DME)

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Bayer have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.